SG11201809687TA - Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors - Google Patents
Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitorsInfo
- Publication number
- SG11201809687TA SG11201809687TA SG11201809687TA SG11201809687TA SG11201809687TA SG 11201809687T A SG11201809687T A SG 11201809687TA SG 11201809687T A SG11201809687T A SG 11201809687TA SG 11201809687T A SG11201809687T A SG 11201809687TA SG 11201809687T A SG11201809687T A SG 11201809687TA
- Authority
- SG
- Singapore
- Prior art keywords
- rhein
- international
- gmbh
- ingelheim
- boehringer ingelheim
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16169356 | 2016-05-12 | ||
| PCT/EP2017/060890 WO2017194453A1 (en) | 2016-05-12 | 2017-05-08 | Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809687TA true SG11201809687TA (en) | 2018-11-29 |
Family
ID=55967162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809687TA SG11201809687TA (en) | 2016-05-12 | 2017-05-08 | Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9926292B2 (sr) |
| EP (1) | EP3455216B1 (sr) |
| JP (1) | JP6639702B2 (sr) |
| KR (1) | KR20190003995A (sr) |
| CN (1) | CN109153664B (sr) |
| AR (1) | AR108462A1 (sr) |
| AU (1) | AU2017262707B2 (sr) |
| CA (1) | CA3023805A1 (sr) |
| CL (1) | CL2018003158A1 (sr) |
| CO (1) | CO2018012020A2 (sr) |
| CY (1) | CY1123744T1 (sr) |
| DK (1) | DK3455216T3 (sr) |
| EA (1) | EA037188B1 (sr) |
| ES (1) | ES2844926T3 (sr) |
| HR (1) | HRP20202078T1 (sr) |
| HU (1) | HUE053312T2 (sr) |
| IL (1) | IL262662B (sr) |
| JO (1) | JOP20170115B1 (sr) |
| LT (1) | LT3455216T (sr) |
| MA (1) | MA44965B1 (sr) |
| MX (1) | MX2018013701A (sr) |
| PE (1) | PE20190151A1 (sr) |
| PH (1) | PH12018502376A1 (sr) |
| PL (1) | PL3455216T3 (sr) |
| PT (1) | PT3455216T (sr) |
| RS (1) | RS61256B1 (sr) |
| SA (1) | SA518400393B1 (sr) |
| SG (1) | SG11201809687TA (sr) |
| SI (1) | SI3455216T1 (sr) |
| TW (1) | TWI746551B (sr) |
| UA (1) | UA121930C2 (sr) |
| WO (1) | WO2017194453A1 (sr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019254371A1 (en) | 2018-04-17 | 2020-10-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| WO2020083264A1 (zh) * | 2018-10-22 | 2020-04-30 | 广东东阳光药业有限公司 | 胍类衍生物及其用途 |
| KR20210084537A (ko) * | 2018-10-29 | 2021-07-07 | 베링거 인겔하임 인터내셔날 게엠베하 | 피리디닐 설폰아미드 유도체, 약제학적 조성물 및 이의 용도 |
| WO2021083209A1 (en) | 2019-10-29 | 2021-05-06 | Eccogene (Shanghai) Co., Ltd. | Ssao inhibitors and use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19518073A1 (de) * | 1995-05-17 | 1996-11-21 | Hoechst Ag | Substituierte Benzyloxycarbonylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| CA2536954C (en) * | 2003-08-29 | 2012-11-27 | Exelixis, Inc. | C-kit modulators and methods of use |
| CA2575411A1 (en) * | 2004-07-27 | 2006-02-02 | Astellas Pharma Inc. | Thiazole derivatives having vap-1 inhibitory activity |
| PL2479165T3 (pl) * | 2009-09-16 | 2018-05-30 | Astellas Pharma Inc. | Związek glicynowy |
| ES2628850T3 (es) * | 2011-03-15 | 2017-08-04 | Astellas Pharma Inc. | Compuesto de guanidina |
| JP6809464B2 (ja) | 2015-08-06 | 2021-01-06 | 宇部興産株式会社 | 置換グアニジン誘導体 |
-
2017
- 2017-05-08 KR KR1020187035976A patent/KR20190003995A/ko active IP Right Grant
- 2017-05-08 DK DK17721706.4T patent/DK3455216T3/da active
- 2017-05-08 EA EA201892539A patent/EA037188B1/ru not_active IP Right Cessation
- 2017-05-08 AU AU2017262707A patent/AU2017262707B2/en not_active Ceased
- 2017-05-08 LT LTEP17721706.4T patent/LT3455216T/lt unknown
- 2017-05-08 CA CA3023805A patent/CA3023805A1/en active Pending
- 2017-05-08 PE PE2018002340A patent/PE20190151A1/es unknown
- 2017-05-08 RS RS20201583A patent/RS61256B1/sr unknown
- 2017-05-08 WO PCT/EP2017/060890 patent/WO2017194453A1/en unknown
- 2017-05-08 SI SI201730584T patent/SI3455216T1/sl unknown
- 2017-05-08 PT PT177217064T patent/PT3455216T/pt unknown
- 2017-05-08 ES ES17721706T patent/ES2844926T3/es active Active
- 2017-05-08 JP JP2018559351A patent/JP6639702B2/ja active Active
- 2017-05-08 PL PL17721706T patent/PL3455216T3/pl unknown
- 2017-05-08 US US15/588,739 patent/US9926292B2/en active Active
- 2017-05-08 MA MA44965A patent/MA44965B1/fr unknown
- 2017-05-08 CN CN201780027576.9A patent/CN109153664B/zh active Active
- 2017-05-08 UA UAA201812102A patent/UA121930C2/uk unknown
- 2017-05-08 MX MX2018013701A patent/MX2018013701A/es unknown
- 2017-05-08 HU HUE17721706A patent/HUE053312T2/hu unknown
- 2017-05-08 EP EP17721706.4A patent/EP3455216B1/en active Active
- 2017-05-08 SG SG11201809687TA patent/SG11201809687TA/en unknown
- 2017-05-11 AR ARP170101262A patent/AR108462A1/es unknown
- 2017-05-11 JO JOP/2017/0115A patent/JOP20170115B1/ar active
- 2017-05-11 TW TW106115558A patent/TWI746551B/zh not_active IP Right Cessation
-
2018
- 2018-10-29 IL IL262662A patent/IL262662B/en unknown
- 2018-11-06 CO CONC2018/0012020A patent/CO2018012020A2/es unknown
- 2018-11-07 SA SA518400393A patent/SA518400393B1/ar unknown
- 2018-11-08 CL CL2018003158A patent/CL2018003158A1/es unknown
- 2018-11-12 PH PH12018502376A patent/PH12018502376A1/en unknown
-
2020
- 2020-12-30 HR HRP20202078TT patent/HRP20202078T1/hr unknown
-
2021
- 2021-01-19 CY CY20211100039T patent/CY1123744T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201806750WA (en) | Substituted 1,2,3-triazoles as nr2b-selective nmda modulators | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201803627XA (en) | N-substituted indole derivatives as pge2 receptor modulators | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201406973PA (en) | Complement pathway modulators and uses thereof | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201407988UA (en) | Process for improved opioid synthesis | |
| SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201809687TA (en) | Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer |